TABLE 1.
Baseline patient characteristics of REduction of Atherothrombosis for Continued Health (REACH) patients from Canada, overall and stratified according to affected arterial beds (n=1976)
| Overall (n=1976) | Multiple risk factors (n=345) | Any 1 site (n=1376) | Any 2 or 3 sites (n=255) | Any CAD (n=1362) | Any CVD (n=394) | Any PAD (n=148) | |
|---|---|---|---|---|---|---|---|
| Demographics | |||||||
| Age, years, mean ± SD | 68.4±9.9 | 67.8±9.9 | 68.1±9.8 | 71.1±9.6 | 68.3±9.8 | 71.1±9.8 | 69.3±9.6 |
| Men | 69.0 | 56.8 | 71.6 | 71.0 | 73.4 | 65.5 | 68.9 |
| Socioeconomic factors | |||||||
| High school not completed | 69.3 | 71.4 | 67.7 | 75.1 | 68.3 | 71.0 | 81.3 |
| Nonactive working status | 74.3 | 76.2 | 72.3 | 82.4 | 73.1 | 82.2 | 79.1 |
| Medical history | |||||||
| Hypercholesterolemia | 84.4 | 86.4 | 84.4 | 81.6 | 86.9 | 72.8 | 81.8 |
| Hypertension | 76.6 | 88.4 | 71.9 | 85.5 | 73.2 | 82.5 | 81.8 |
| Diabetes mellitus* | 44.1 | 84.6 | 33.7 | 45.1 | 36.5 | 35.4 | 48.0 |
| Smoking status | |||||||
| Former | 45.7 | 31.6 | 48.8 | 47.8 | 49.4 | 44.9 | 50.7 |
| Current | 15.4 | 20.9 | 13.2 | 19.6 | 13.7 | 13.5 | 30.4 |
| Obesity† | 51.7 | 68.5 | 48.2 | 47.9 | 48.1 | 48.5 | 46.9 |
| Overweight (BMI 25 kg/m2 to <30 kg/m2) | 41.8 | 39.5 | 42.0 | 43.8 | 42.6 | 41.3 | 44.2 |
| Class I (BMI 30 kg/m2 to <35 kg/m2) | 22.9 | 25.1 | 22.6 | 21.9 | 23.1 | 22.0 | 15.0 |
| Class II (BMI 35 kg/m2 to <40 kg/m2) | 6.9 | 9.4 | 6.9 | 3.6 | 6.6 | 3.9 | 6.1 |
| Class III (BMI ≥40 kg/m2) | 3.4 | 6.5 | 2.9 | 2.4 | 3.0 | 2.1 | 2.0 |
| Baseline medication use | |||||||
| Antiplatelet agents | |||||||
| Acetylsalicylic acid | 79.0 | 66.4 | 83.4 | 72.2 | 83.6 | 68.4 | 81.0 |
| Other | 17.0 | 1.7 | 19.0 | 27.1 | 18.8 | 30.9 | 19.0 |
| Oral anticoagulants | 10.9 | 6.0 | 10.1 | 21.6 | 12.1 | 19.8 | 10.9 |
| Nonsteroidal anti-inflammatory drugs | 10.2 | 13.2 | 8.5 | 15.5 | 9.8 | 13.1 | 9.2 |
| Lipid-lowering agents | |||||||
| Statins | 81.5 | 77.7 | 82.2 | 83.1 | 85.3 | 72.8 | 81.1 |
| Other | 8.0 | 10.1 | 8.1 | 4.7 | 8.1 | 4.1 | 6.8 |
| Cardiovascular agents | |||||||
| Calcium channel blockers | 34.6 | 34.8 | 32.6 | 44.9 | 34.6 | 36.5 | 47.9 |
| Beta-blockers | 51.4 | 21.3 | 57.5 | 59.0 | 65.2 | 37.2 | 45.9 |
| Nitrates/other antianginal drugs | 22.8 | 1.4 | 25.0 | 40.1 | 32.3 | 19.9 | 28.0 |
| Diuretics | 39.9 | 51.3 | 34.8 | 52.2 | 36.8 | 45.9 | 49.0 |
| Angiotensin-converting enzyme inhibitors | 57.0 | 57.7 | 56.8 | 57.3 | 58.1 | 52.7 | 57.1 |
| Angiotensin II receptor blockers | 23.5 | 33.4 | 20.6 | 25.7 | 21.5 | 23.3 | 22.9 |
| Other antihypertensive agents | 5.1 | 6.4 | 4.1 | 8.7 | 5.3 | 4.6 | 6.9 |
| Claudication medications‡ | 1.4 | 0.3 | 1.2 | 3.9 | 1.5 | 1.6 | 8.5 |
| Antidiabetic agents | |||||||
| Insulin | 8.8 | 14.0 | 6.8 | 12.2 | 8.3 | 7.2 | 14.3 |
| Biguadines | 25.7 | 55.9 | 18.7 | 23.0 | 20.1 | 17.6 | 23.0 |
| Sulfonylureas | 19.5 | 43.2 | 13.9 | 17.6 | 14.6 | 14.5 | 16.9 |
| Thiazolidinediones | 9.0 | 22.9 | 5.9 | 7.5 | 6.0 | 6.6 | 6.8 |
| Other | 2.8 | 6.2 | 1.7 | 3.9 | 2.1 | 2.1 | 5.5 |
| Any antidiabetic agent | 39.3 | 80.6 | 29.0 | 39.2 | 31.8 | 29.4 | 39.9 |
| Average medications per patient, n§ | 5.1 | 5.2 | 4.9 | 5.8 | 5.2 | 4.8 | 5.4 |
Data presented as % unless otherwise indicated.
*
Type 1 or 2 diabetes mellitus currently treated with hypoglycemic agents, or history of diabetes;
†
Men with a waist circumference of 102 cm or larger, and women with a waist circumference of 88 cm or larger;
‡
Claudication medications included cilostazol, pentoxifylline, buflomedil, naftidrofuryl and Ginkgo biloba;
§
Refers to the overall number of medications. BMI Body mass index; CAD Coronary artery disease; CVD Cerebrovascular disease; PAD Peripheral arterial disease